Haleon Pakistan Limited (PSX:HALEON)

Market Cap	92.26B
Revenue (ttm)	37.21B
Net Income (ttm)	4.58B
Shares Out	117.05M
EPS (ttm)	39.11
PE Ratio	20.15
Forward PE	n/a
Dividend	20.00 (2.54%)
Ex-Dividend Date	Mar 11, 2025

Volume	31,456
Average Volume	192,214
Open	790.01
Previous Close	789.33
Day's Range	787.00 - 794.00
52-Week Range	182.50 - 975.00
Beta	0.56
RSI	43.84
Earnings Date	Apr 25, 2025

About Haleon Pakistan

Haleon Pakistan Limited engages in the manufacture, marketing, and sale of consumer healthcare products in Pakistan, Africa, Australia, North America, Asia, the Middle East, and Europe. The company offers oral health, pain relief, vitamins and mineral supplements, and respiratory health products. It sells its products under the Panadol, CaC-1000 Plus, Sensodyne, paradontax, T-Day, ENO, Hydrozole, Qalsium-D, and Voltral Emulgel brands. The company also exports its products to the Philippines, Vietnam, and East West Africa region. The company was...

• Industry: Pharmaceutical Preparations
• Founded: 2015
• Employees: 450
• Stock Exchange: Pakistan Stock Exchange
• Ticker Symbol: HALEON

Financial Performance

In 2024, Haleon Pakistan's revenue was 37.21 billion, an increase of 17.70% compared to the previous year's 31.61 billion. Earnings were 4.58 billion, an increase of 359.85%.